Navigation Links
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial
Date:6/16/2008

testing; the therapeutic and commercial value of XL184 and our other compounds; our ability to initiate clinical trials for XL184 at the referenced times; and our ability to enter into new collaborations, continue existing collaborations and receive milestones and royalties under our collaborative agreements. These and other risk factors are discussed under "Risk Factors" and elsewhere in our quarterly report on Form 10-Q for the quarter ended March 28, 2008, and other filings with the Securities and Exchange Commission. We expressly disclaim any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Exelixis Announces June 19 Webcast of Presentation at the William Blair 28th Annual Growth Stock Conference
2. Exelixis Receives $150 Million Funding Commitment From Deerfield Management
3. Exelixis Announces June 5 Webcast of Conference Call Regarding Its $150 Million Funding Commitment from Deerfield Management
4. Exelixis Announces June 10 Webcast of Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference
5. REMINDER: Exelixis Will Webcast Its June 2 Investor and Analyst Briefing at ASCO
6. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
7. Exelixis Announces May 13 Webcast of Presentation at the Bank of America Health Care Conference
8. Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call
9. Exelixis Announces April 30 Webcast of Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... DUBLIN , July 10, 2014 ... the addition of the "International Photonic Integrated ... - Forecasts to 2019" report to their ... The concept of photonic integration traces ... twentieth century. The promise of photonic integration went ...
(Date:7/10/2014)... June 17, 2014 Using microscopic polymer light ... gases, researchers at MIT,s Quantum Photonics Laboratory have ... in the parts-per-billion range. Optical sensors are ideal ... high signal-to-noise ratio, compact, lightweight nature, and immunity ... sensors had been developed before, the MIT team ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Swell new sensors 2
... CV Therapeutics,Inc. (Nasdaq: CVTX ) announced today that ... (EMEA) for ranolazine for,the treatment of patients with chronic ... approval follows a positive opinion from the EMEA,Committee for ... 2008., Ranolazine is approved for use in Europe ...
... 10 Quest Diagnostics,Incorporated (NYSE: DGX ), the ... today that its second-quarter,2008 results will be made public ... it will hold its quarterly conference call with investors,to ... that day., The public may access the conference ...
... ALXN ), today announced that the Company will,conduct ... July 29, 2008, at,10:00 a.m. Eastern Time (ET), in ... second quarter ended June 30, 2008. Alexion,anticipates releasing its ... 2008., To participate in this conference call, dial ...
Cached Biology Technology:CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 2CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 3Quest Diagnostics to Release Second Quarter 2008 Financial Results 2
(Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
(Date:7/11/2014)... 2014 The increased risk of kidney injury related ... fluids reflects the mass of HES molecules, according to ... journal of the International Anesthesia Research Society (IARS). , ... effect of HES on cultured human renal proximal tubule ... Wunder and colleagues of University Hospital Wrzburg, Austria. ...
(Date:7/11/2014)... addition to the hippocampus, the marginal division of ... memory. What is the impact degree of substance ... and memory function? Yan Yu and his team, ... found, using immunofluorescence staining, that substance P receptor, ... and striatal marginal division of normal rats. Unilateral ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... Research explains the American obesity paradox: the parallel rise in ... series of four studies, the researchers reveal that we over-generalize ... desserts containing up to 131% more calories when the main ... white view, most food is good or not good, explain ...
... priorities can drive local waste partnerships towards the achievement ... sustainable waste management objectives, a study funded by the ... of waste and disposing of it in environmentally acceptable ... other areas of public service delivery, partnership working is ...
... to tinker with a single amino acid of an ... according to molecular biologists who say the discovery could ... of making vaccines. "We have successfully tested this technique ... of biochemistry and molecular biology at Penn State. "And ...
Cached Biology News:You're likely to order more calories at a 'healthy' restaurant 2Central targets may hinder wider waste management objectives 2Central targets may hinder wider waste management objectives 3Discovery may help defang viruses 2Discovery may help defang viruses 3
20X TE buffer *RNase free*...
Sheep Serum US Origin...
Human LAIR2 Biotinylated Affinity Purified PAb...
... Lacks the mycobacteria found in Complete ... this reason, Incomplete, Freund's Adjuvant ... may be used to produce water-in-oil emulsions of ... high and long-lasting antibody responses which can be ...
Biology Products: